Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02358863 · ClinicalTrials.gov registry record · NA
Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach
A NA study, sponsored by Georgetown University.
- Terminated
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT02358863 is a NA study that was terminated before completion, run by Georgetown University. The registered enrollment target is 13 participants.
The verdict
NCT02358863, a NA study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether molecular profile-directed therapy (otherwise known as personalized treatment) can improve the effectiveness of standard chemotherapy combinations for patients with esophagogastric adenocarcinoma. A series of tests will be performed on a sample of tumor; based on the results of these tests, a patient will be assigned to a chemotherapy treatment.
Interventions
- DRUG Modified FOLFOX6
- DRUG Docetaxel/Capecitabine
- DRUG Cisplatin/Irinotecan
- DRUG Cisplatin/Docetaxel
- DRUG IRI/EPI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-02 |
| Est. Completion | 2016-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02358863
The ClinicalTrials.gov registry entry for NCT02358863 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Modified FOLFOX6 is the first listed.
NCT02358863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02358863 about?
NCT02358863 is a clinical study titled "Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach". The purpose of this study is to determine whether molecular profile-directed therapy (otherwise known as personalized treatment) can improve the effectiveness of standard chemotherapy combinations for patients with esophagogastric adenocarcinoma. A series of tests will be performed on a sample of tu...
What is the current status of trial NCT02358863?
This trial is currently terminated. It is a NA study. The enrollment target is 13 participants. The study started on 2015-02. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02358863?
The interventions under investigation include: Modified FOLFOX6 (DRUG), Docetaxel/Capecitabine (DRUG), Cisplatin/Irinotecan (DRUG), Cisplatin/Docetaxel (DRUG), IRI/EPI (DRUG).
Who is sponsoring clinical trial NCT02358863?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.